Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo

Andres, 2020, High-throughput generation of bispecific binding proteins by sortase A-mediated coupling for direct functional screening in cell culture, Mol. Cancer Ther., 19, 1080, 10.1158/1535-7163.MCT-19-0633 Baggio, 2008, An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis, Gastroenterology, 134, 1137, 10.1053/j.gastro.2008.01.017 Balakrishnan, 2019, Multispecific targeting with synthetic Ankyrin repeat motif chimeric antigen receptors, Clin. Cancer. Res., 25, 7506, 10.1158/1078-0432.CCR-19-1479 Baldeweg, 2000, Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR), Eur. J. Clin. Invest., 30, 45, 10.1046/j.1365-2362.2000.00597.x Binz, 2017, Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin(R) drug candidate, mAbs, 9, 1262, 10.1080/19420862.2017.1305529 Brown, 2018, Newer GLP-1 receptor agonists and obesity-diabetes, Peptides, 100, 61, 10.1016/j.peptides.2017.12.009 Caputi, 2020, Beyond antibodies: ankyrins and DARPins. From basic research to drug approval, Curr. Opin. Pharmacol., 51, 93, 10.1016/j.coph.2020.05.004 Cho, 2012, Targeting the glucagon receptor family for diabetes and obesity therapy, Pharmacol. Ther., 135, 247, 10.1016/j.pharmthera.2012.05.009 Deacon, 1998, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig, Diabetes, 47, 764, 10.2337/diabetes.47.5.764 Frejd, 2017, Affibody molecules as engineered protein drugs, Exp. Mol. Med., 49, e306, 10.1038/emm.2017.35 Gao, 2012, A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo, J. Pharm. Pharmacol., 64, 1646, 10.1111/j.2042-7158.2012.01545.x Greenfield, 2006, Using circular dichroism spectra to estimate protein secondary structure, Nat. Protoc., 1, 2876, 10.1038/nprot.2006.202 He, 2019, Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes, J. Control Release, 301, 119, 10.1016/j.jconrel.2019.03.014 Hossain, 2007, Obesity and diabetes in the developing world–a growing challenge, N. Engl. J. Med., 356, 213, 10.1056/NEJMp068177 Ishida, 2013, Anti-polyethyleneglycol antibody response to PEGylated substances, Biol. Pharm. Bull., 36, 889, 10.1248/bpb.b13-00107 Jacobs, 2015, Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics, Protein Eng. Des. Sel., 28, 385, 10.1093/protein/gzv040 Jonsson, 2008, Engineering of a femtomolar affinity binding protein to human serum albumin, Protein Eng. Des. Sel., 21, 515, 10.1093/protein/gzn028 Jun, 2015, Cytotoxicity and biological efficacy of exendin-4-encapsulated solid lipid nanoparticles in INS-1 cells, J. Nanomater., 2015, 10.1155/2015/753569 Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology, 136, 3585, 10.1210/endo.136.8.7628397 Kim, 2010, Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides, J. Pharmacol. Exp. Ther., 334, 682, 10.1124/jpet.110.166470 Kim, 2021, Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity, Biologicals, 69, 49, 10.1016/j.biologicals.2020.11.005 Kjeldsen, 2020, Dually reactive long recombinant linkers for bioconjugations as an alternative to PEG, ACS Omega, 5, 19827, 10.1021/acsomega.0c02712 Levy, 2014, Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action, PLOS One, 9, e87704, 10.1371/journal.pone.0087704 Li, 2017, The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and beta-cell function in spontaneous diabetic KKAy mice, BMC Pharmacol. Toxicol., 18, 48, 10.1186/s40360-017-0143-8 Li, 2016, Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL, J. Control Release, 228, 96, 10.1016/j.jconrel.2016.03.004 Liao, 2022, Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys, Eur. J. Pharm. Sci., 175, 10.1016/j.ejps.2022.106218 Ma, 2019, Pharmacological signatures of the exenatide nanoparticles against hepatic ischemia/reperfusion-induced pancreatic injury, Transplant. Proc., 51, 960, 10.1016/j.transproceed.2019.01.031 Mu, 2013, Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation, PLOS One, 8, e68559, 10.1371/journal.pone.0068559 Podust, 2016, Extension of in vivo half-life of biologically active molecules by XTEN protein polymers, J. Control Release, 240, 52, 10.1016/j.jconrel.2015.10.038 Podust, 2013, Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer, Protein Eng. Des. Sel., 26, 743, 10.1093/protein/gzt048 Reed, 2020, Recent advances in understanding the role of glucagon-like peptide 1, F1000Research, 9, 239, 10.12688/f1000research.20602.1 Saeedi, 2019, Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, Diabetes Res. Clin. Pract., 157, 10.1016/j.diabres.2019.107843 Saisho, 2015, β-cell dysfunction: its critical role in prevention and management of type 2 diabetes, World J. Diabetes, 6, 109, 10.4239/wjd.v6.i1.109 Schellenberger, 2009, A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner, Nat. Biotechnol., 27, 1186, 10.1038/nbt.1588 Sharma, 2018, Recent updates on GLP-1 agonists: current advancements & challenges, Biomed. Pharmacother., 108, 952, 10.1016/j.biopha.2018.08.088 Siegel, 2021, A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction, Basic Res. Cardiol., 116, 17, 10.1007/s00395-021-00849-9 Steeland, 2016, Nanobodies as therapeutics: big opportunities for small antibodies, Drug Discov. Today, 21, 1076, 10.1016/j.drudis.2016.04.003 Steiner, 2017, Half-life extension using serum albumin-binding DARPin(R) domains, Protein Eng. Des. Sel., 30, 583, 10.1093/protein/gzx022 Stumpp, 2008, DARPins: a new generation of protein therapeutics, Drug Discov. Today, 13, 695, 10.1016/j.drudis.2008.04.013 Stumpp, 2020, Beyond antibodies: the DARPin((R)) drug platform, Biodrugs, 34, 423, 10.1007/s40259-020-00429-8 Su, 2020, Ferritin-displayed GLP-1 with improved pharmacological activities and pharmacokinetics, Mol. Pharm., 17, 1663, 10.1021/acs.molpharmaceut.0c00098 Sun, 2019, Novel mono-lipidated dimeric glucagon-like peptide-1 receptor agonist with improved long-acting and hypoglycemic activity, RSC Adv., 9, 9654, 10.1039/C9RA00833K Sun, 2015, Coumaglutide, a novel long-acting GLP-1 analog, inhibits beta-cell apoptosis in vitro and invokes sustained glycemic control in vivo, Eur. J. Pharmacol., 767, 211, 10.1016/j.ejphar.2015.10.028 Tan, 2021, Albumin-binding domain extends half-life of glucagon-like peptide-1, Eur. J. Pharmacol., 890, 10.1016/j.ejphar.2020.173650 Tan, 2021, Generation of novel long-acting GLP-1R agonists using DARPins as a scaffold, Int. J. Pharm., 607, 10.1016/j.ijpharm.2021.121043 Tilinca, 2021, A 2021 update on the use of liraglutide in the modern treatment of 'Diabesity': a narrative review, Medicina (Kaunas), 57, 669, 10.3390/medicina57070669 Verma, 2017, Obesity and diabetes: an update, Diabetes Metab. Syndr., 11, 73, 10.1016/j.dsx.2016.06.017 Wang, 2020, Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice, Biomed. Pharmacother., 125, 10.1016/j.biopha.2020.109914 Wilding, 2021, Once-weekly semaglutide in adults with overweight or obesity, N. Engl. J. Med., 384, 989, 10.1056/NEJMoa2032183 Yang, 2020, New generation oxyntomodulin peptides with improved pharmacokinetic profiles exhibit weight reducing and anti-steatotic properties in mice, Bioconjug. Chem., 31, 1167, 10.1021/acs.bioconjchem.0c00093 Yu, 2018, Battle of GLP-1 delivery technologies, Adv. Drug Deliv. Rev., 130, 113, 10.1016/j.addr.2018.07.009 Zahnd, 2010, Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size, Cancer Res., 70, 1595, 10.1158/0008-5472.CAN-09-2724 Zhang, 2014, A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys, Biochem. Biophys. Res. Commun., 445, 511, 10.1016/j.bbrc.2014.02.045 Zhang, 2010, PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Comput. Methods Programs Biomed., 99, 306, 10.1016/j.cmpb.2010.01.007 Zhang, 2015, Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody, Angew. Chem. Int. Ed. Engl., 54, 2126, 10.1002/anie.201410049 Zhong, 2018, Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics, Eur. J. Med. Chem., 150, 841, 10.1016/j.ejmech.2018.03.050